Primary Sclerosing Cholangitis clinical trials at UCSF

• Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

  open to eligible people ages 18-75

  The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

  San Francisco, California and other locations

Last updated: March 25, 2021